IP Library Granted Patent US 9,883,998
Granted Patent B2
US 9,883,998 · App. 14/849,413 · Granted Feb 6, 2018

Methods for lightening skin using arbutin compositions

Inventors: Judy Hattendorf (Marina Del Ray, CA); Steve Carlson (San Mateo, CA)
Assignee: OMP, Inc.
A61K8/602A61K8/361A61Q19/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,883,998
App. No.
14/849,413
Granted
Feb 6, 2018
Kind
B2
Abstract

Arbutin-containing compositions are useful for topical application to provide enhanced luminosity, brightening or lightening to the skin of a user and are at least 85% as efficacious (with regard to skin lightening, when used alone or in a system as measured by Chromameter® b* parameter values) as substantially corresponding compositions containing hydroquinone in an mount from about the same molar amount to about 1.5 times the molar amount of arbutin.

Claims (35)

1. A method for lightening skin of a subject, the method comprising applying to an area of skin of the subject an arbutin-containing composition, wherein the arbutin-containing composition comprises:

an aqueous phase comprising:

arbutin in an amount from 5% to 10% by weight of the total composition;

one or more preservatives in an amount from about 0.01% to about 5% by weight of the total composition;

one or more chelating agents in an amount from about 0.01% to about 5% by weight of the total composition;

one or more humectants in an amount from about 1% to about 20% by weight of the total composition;

one or more emulsifiers in an amount from about 1% to about 20% by weight of the total composition;

one or more pH adjustment agents in an amount sufficient to adjust the pH of the aqueous phase to a pH of about 2 to about 4; and

one or more reducing agents in an amount from about 0.1% to about 10% by weight of the total composition;

and further comprises an oil phase comprising:

one or more emollients in an amount from about 2% to about 25% by weight of the total composition; and

one or more antioxidants in an amount from about 0.1% to about 2% by weight of the total composition.

2. The method of claim 1 , wherein the arbutin-containing composition comprises 7% arbutin.

3. The method of claim 1 , wherein in the aqueous phase of the arbutin-containing composition, the one or more preservatives are selected from the group consisting of methylparaben, propylparaben, butylparaben, or a combination thereof; the one or more chelating agents is edetate disodium; the one or more humectants is glycerin; the one or more emulsifiers are selected from the group consisting of sodium lauryl sulfate, triethanolamine salicylate, or a combination thereof; the one or more pH adjustment agents is lactic acid; and the one or more reducing agents are selected from the group consisting of sodium metabisulfite, ascorbic acid, or a combination thereof.

4. The method of claim 1 , wherein in the oil phase of the arbutin-containing composition, the one or more emollients are selected from the group consisting of cetyl alcohol, stearyl alcohol, or a combination thereof, and the one or more antioxidants are selected from the group consisting of tocopheryl acetate, butylated hydroxytoluene (BHT), or a combination thereof.

5. The method of claim 1 , wherein prior to applying the arbutin-containing composition to the area of skin, the method further comprises applying a cationic toner to the area of skin.

6. The method of claim 1 , wherein after applying the arbutin-containing composition to the area of skin, the method further comprises applying tretinoin to the area of skin.

7. The method of claim 1 , wherein the arbutin-containing composition is applied daily for at least 8 weeks.

8. A method for lightening skin of a subject, the method comprising:

(a) applying to an area of skin of the subject a cationic toner;

(b) subsequent to the step of applying the cationic toner, applying to the cationic toner-treated area of skin an arbutin-containing composition, wherein the arbutin-containing composition comprises an aqueous phase comprising arbutin in an amount from 5% to 10% by weight of the total composition; and

(c) subsequent to the step of applying the arbutin-containing composition, applying to the cationic toner-treated and arbutin-containing composition-treated area of skin a composition comprising tretinoin.

9. The method of claim 8 , wherein the aqueous phase of the arbutin-containing composition further comprises:

one or more preservatives;

one or more chelating agents;

one or more humectants;

one or more emulsifiers;

one or more pH adjustment agents; and

one or more reducing agents.

10. The method of claim 9 , wherein the one or more preservatives are present in an amount from about 0.01 to about 5% by weight of the total composition; the one or more chelating agents are present in an amount from about 0.01 to about 5% by weight of the total composition; the one or more humectants are present in an amount from about 1 to about 20% by weight of the total composition; the one or more emulsifiers are present in an amount from about 1 to about 20% by weight of the total composition; the one or more pH adjustment agents are present in an amount from about 0.01 to about 5% by weight of the total composition; and the one or more reducing agents are present in an amount from about 0.1 to about 10% by weight of the total composition.

11. The method of claim 8 , wherein the arbutin-containing composition further comprises an oil phase comprising one or more emollients and one or more antioxidants.

12. The method of claim 11 , wherein the one or more emollients are present in an amount from about 2 to about 25% by weight of the total composition, and one or more antioxidants are present in an amount from about 0.1 to about 2% by weight of the total composition.

13. The method of claim 8 , wherein the arbutin-containing composition comprises 7% arbutin.

14. The method of claim 8 , wherein the composition comprising tretinoin comprises 0.025% tretinoin.

15. The method of claim 8 , wherein the cationic toner, the arbutin-containing composition, and the composition comprising tretinoin are applied daily for at least 8 weeks.

Assignments (17)
SECURITY INTEREST Recorded Jul 30, 2026
From: OBAGI COSMECEUTICALS LLC
To: MIDCAP FINANCIAL TRUST, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 075464/0639 →
RELEASE OF SECURITY INTEREST Recorded Nov 17, 2025
From: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 072928/0385 →
PATENT SECURITY AGREEMENT Recorded Nov 17, 2025
From: OBAGI COSMECEUTICALS LLC
To: LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 073625/0459 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2025
From: JPMORGAN CHASE BANK, N.A.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 070592/0979 →
SECURITY INTEREST Recorded Mar 18, 2025
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070546/0595 →
SECURITY INTEREST Recorded Aug 1, 2022
From: OBAGI COSMECEUTICALS LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060690/0148 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2022
From: TCW ASSET MANAGEMENT COMPANY LLC
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 060668/0771 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 055652/0735 →
SECURITY INTEREST Recorded Mar 16, 2021
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 055613/0083 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 13, 2018
From: OBAGI COSMECEUTICALS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047873/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OMP, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0244 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OMP, INC.
Reel/Frame 044765/0176 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OMP, INC.
Reel/Frame 044439/0790 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OMP, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0751 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2015
From: HATTENDORF, JUDY; CARLSON, STEVE
To: OMP, INC.
Reel/Frame 036543/0357 →
Continuity (3)
Continuation 12743127
Provisional Application 61003015 · Nov 14, 2007
Related Publication 20160067165A1 · Mar 10, 2016